🚨 New Trial Spotlight The Do IT Study found that in people with HIV and obesity, switching from an INSTI + TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change. 📖 Read the study: academic.oup.com/cid/article/...
A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391)
The prospective, randomized, multicenter A5391 trial found that switching from INSTI- and TAF-containing antiretroviral therapy to an NNRTI, with or withou
academic.oup.com